drugset / Trial / NCT07180862
A Study Evaluating BAT3306 Compared With Keytruda® in NSCLC Cancer Participants
RandomizedParallel-groupTriple-blindTreatment
Summary
Comparing the PK similarity of BAT3306 and Keytruda; in NSCLC participants who were completely removed by surgery as an auxiliary treatment
Timeline
- Start
- 2025-10-14
- Primary completion
- 2027-02-28
- Completion
- 2027-11-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | BAT3306 | Monoclonal antibody | 200 mg | Intravenous |
| Comparator | US-Keytruda® | Unknown | 200 mg | Intravenous |